Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 3/20 | 0.34 |
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | DDX3X | O00571 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420816 | 0.86 | PDE2A (0.34) | GCGCHRM1FFAR4ACACBDDX3X | |
| SCHEMBL12989178 | 0.84 | CHRM1 (0.40) | CHRM1FFAR4AXLMERTK | |
| SCHEMBL15420585 | 0.84 | CHRM1 (0.40) | CHRM1FFAR4AXLMERTK | |
| SCHEMBL12989171 | 0.84 | CHRM1 (0.40) | CHRM1FFAR4AXLMERTK | |
| SCHEMBL15420757 | 0.84 | DDB1 (0.41) | CHRM1FFAR4ACACB | |
| SCHEMBL12989884 | 0.83 | CHRM1 (0.42) | CHRM1AXLMERTKACACBDDX3X | |
| SCHEMBL12989883 | 0.83 | CHRM1 (0.42) | CHRM1AXLMERTKACACBDDX3X | |
| SCHEMBL21795642 | 0.83 | GCG (0.34) | GCGFFAR4DGAT1AXLMERTK | |
| SCHEMBL15420612 | 0.79 | GCGR (0.44) | GCGCHRM1FFAR4 | |
| SCHEMBL15420716 | 0.77 | CHRM1 (0.39) | CHRM1FFAR4AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | GCG 4793/4885CHRM1 227/4885FFAR4 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.